Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 92, Issue 16, 2000, Pages 1321-1329

  Berthelot, Jean Marie ^a   Will, B Phyllis ^a   Evans, William K ^b,c,e   Coyle, Douglas ^d   Earle, Craig C ^b,c   Bordeleau, Louise ^b,c  

^a STATISTICS CANADA   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e CANCER CARE ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOFOS; GEMCITABINE; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; TERMINAL CARE;

EID: 0034674899     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.16.1321     Document Type: Article

References (37)

1. Cancer statistics
2. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer
3. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma
4. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?
5. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer
6. Is chemotherapy with cisplatin useful in non small cell bronchial cancer at stage IV? Results of a randomized study
7. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial
8. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer
9. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer
10. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small lung cancer
11. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?
12. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
13. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer
14. The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
15. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer
16. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
17. Management of metastatic non-small-cell lung cancer and a consideration of cost
18. POHEM - A framework for understanding and modelling the health of human populations
19. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs
20. The cost of radiotherapy at an Ontario regional cancer centre: A re-evaluation
21. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: An expanded analysis
22. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
23. Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter, extended phase II study
24. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer
25. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer
26. Phase II study of Taxol in patients with untreated advanced non-small cell-lung cancer
27. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results
28. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
29. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer
30. Principles of cost-effective resource allocation in health care organizations
31. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
32. Recent advances in the treatment of non-small-cell lung cancer
33. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer
34. Some guidelines on the use of cost-effectiveness league tables
35. Theoretical foundations of cost-effectiveness analysis